Abbott Laboratories Corporation

Other

Icahn School of Medicine at Mount Sinai

Bryan C Tieman

David J Hawksworth

Robert N Ziemann

Susan E Brophy

Joan D Tyner

Bailin Tu

A Scott Muerhoff

Christopher C Marohnic

April Ahlberg

Kathy Otis

Larry G Birkenmeyer

Robert William Siegel

Anthony Scott Muerhoff

Dinesh O Shah

Barry Lee Dowell

Cheng Zhao

Carol S Ramsay

Carolyn J Strobel

Philip M Hemken

Mary S Pinkus

Jessie W Shih

Lowell J Tyner, Legal Representative

Suresh M Desai

Saul A Datwyler

Qiaoqiao Ruan

Sergey Y Tetin

Frank C Grenier

Ryan F Workman

Edward T Olejniczak

Andrea Branch

Matthew S Matias

David J Daghfal

Dominick L Pucci

Sharmila Manoj

Zhiguang Yu

Francis Eng

David J Dagfal

Don C Laird

Joan D(deceased) Tyner

Barry L Dowell

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.

Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies

Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.

Anti-GP73 monoclonal antibodies and methods of obtaining the same

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.

The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of

[object Object]

The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.

HCV core lipid binding domain monoclonal antibodies

The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.

Antibodies that bind to mammalian NGAL and uses thereof

An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid.

Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making

The present invention relates to antibodies that immunospecifically bind to human brain natriuretic peptide or a human brain natriuretic peptide fragment with a high binding affinity, methods for producing and selecting said antibodies, immunoassays for human brain natriuretic peptide or a human brain natriuretic peptide fragment that employ said antibodies and therapeutic compositions containing said antibodies.

Human BNP immunospecific antibodies

Growing community of inventors

Elmhurst, IL, United States of America

Bryan C Tieman